BR112014015101A8 - métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos - Google Patents

métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos

Info

Publication number
BR112014015101A8
BR112014015101A8 BR112014015101A BR112014015101A BR112014015101A8 BR 112014015101 A8 BR112014015101 A8 BR 112014015101A8 BR 112014015101 A BR112014015101 A BR 112014015101A BR 112014015101 A BR112014015101 A BR 112014015101A BR 112014015101 A8 BR112014015101 A8 BR 112014015101A8
Authority
BR
Brazil
Prior art keywords
polypeptide
membrane
interest
effluent
ion exchange
Prior art date
Application number
BR112014015101A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014015101A2 (pt
Inventor
Michael Brown Arick
Ellen Thayer Brooke
John Dowd Christopher
Jospeh Bill Jerome
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47430154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014015101(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112014015101A2 publication Critical patent/BR112014015101A2/pt
Publication of BR112014015101A8 publication Critical patent/BR112014015101A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
BR112014015101A 2011-12-22 2012-12-18 métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos BR112014015101A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579285P 2011-12-22 2011-12-22
PCT/US2012/070373 WO2013096322A1 (en) 2011-12-22 2012-12-18 Ion exchange membrane chromatography

Publications (2)

Publication Number Publication Date
BR112014015101A2 BR112014015101A2 (pt) 2017-06-13
BR112014015101A8 true BR112014015101A8 (pt) 2021-06-08

Family

ID=47430154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015101A BR112014015101A8 (pt) 2011-12-22 2012-12-18 métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos

Country Status (21)

Country Link
US (3) US10364268B2 (enExample)
EP (2) EP2794635B8 (enExample)
JP (5) JP6605202B2 (enExample)
KR (3) KR20210025692A (enExample)
CN (2) CN108892706A (enExample)
AR (1) AR089362A1 (enExample)
AU (3) AU2012355356B2 (enExample)
BR (1) BR112014015101A8 (enExample)
CA (1) CA2859376C (enExample)
ES (1) ES2697676T3 (enExample)
HR (1) HRP20181846T1 (enExample)
IL (2) IL267585B (enExample)
MX (2) MX360453B (enExample)
MY (1) MY172426A (enExample)
PL (1) PL2794635T3 (enExample)
RU (1) RU2648999C2 (enExample)
SG (1) SG11201403437TA (enExample)
SI (1) SI2794635T1 (enExample)
TR (1) TR201815709T4 (enExample)
WO (1) WO2013096322A1 (enExample)
ZA (2) ZA201404593B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181846T1 (hr) 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
EP3698870A1 (en) 2013-12-12 2020-08-26 EMD Millipore Corporation Protein separations using an acrylamide containing filter
EP4671270A3 (en) * 2013-12-27 2026-03-18 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
CN104693303B (zh) * 2015-02-28 2018-03-13 苏州金盟生物技术有限公司 一种蛋白制品中的核酸去除方法
MA42613A (fr) 2015-08-13 2018-06-20 Amgen Inc Filtration en profondeur chargée de protéines de liaison à un antigène
GB201711481D0 (en) 2017-07-17 2017-08-30 Ucb Biopharma Sprl Protein purification
EP3546475A1 (en) * 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
US10792618B2 (en) 2018-06-19 2020-10-06 Sartorius Stedim Biotech Gmbh Particle separation and/or purification of a fluid
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
PT3837273T (pt) * 2018-08-14 2025-12-26 Bristol Myers Squibb Co Recuperação melhorada de proteínas
GB201815405D0 (en) * 2018-09-21 2018-11-07 Fujifilm Mfg Europe Bv Membranes suitable for detecting, filtering and/or purifying biomolecules
EP3899526B1 (en) * 2018-12-21 2024-05-01 Solventum Intellectual Properties Company Method for testing a chromatography device used for ion exchange
TWI870412B (zh) * 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法
WO2021150674A1 (en) * 2020-01-24 2021-07-29 Alkermes, Inc. Methods of purification
US11416468B2 (en) * 2020-07-21 2022-08-16 International Business Machines Corporation Active-active system index management
CN116371011B (zh) * 2023-05-26 2023-08-18 湖南杰萃生物技术有限公司 一种从桑叶中提取黄酮和生物碱的方法
CN117866038B (zh) * 2024-03-11 2024-05-28 北京百力格生物科技有限公司 纯化含有宿主核酸的带亲和标签的酸性蛋白的方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (enExample)
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
JPS6150925A (ja) * 1984-08-17 1986-03-13 Toray Ind Inc 抗原または抗体の精製方法
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3853610T3 (de) * 1987-10-23 2004-05-13 Schering Corp. Verfahren zur Proteinreinigung.
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989012463A1 (en) 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2844346B2 (ja) * 1989-05-31 1999-01-06 昭 梶 新規ペプチドならびに新規ｄｎａ
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
DK0656789T3 (da) 1992-08-21 1998-08-24 Genentech Inc Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JP4057049B2 (ja) * 1993-09-21 2008-03-05 ヘモソル インコーポレーテッド 置換クロマトグラフィー法および精製ヘモグロビン産物
DE69405251T2 (de) 1993-12-10 1998-02-05 Genentech Inc Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika
MX9602818A (es) 1994-01-18 1997-06-28 Genentech Inc Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
WO1995023865A1 (en) 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
JP4864175B2 (ja) 1996-01-23 2012-02-01 ジェネンテック， インコーポレイテッド 発作に関する抗―ｃｄ１８抗体
CA2242931A1 (en) * 1996-01-31 1997-08-07 David Francis Elgar Production of an immunoglobulin enriched fraction from whey protein solutions
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DK0941344T3 (da) 1996-11-27 2004-09-27 Genentech Inc Humaniserede anti-CD11a-antistoffer
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US6054293A (en) 1997-07-08 2000-04-25 The Regents Of The University Of California Semaphorin receptors
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
RU2270029C2 (ru) 1999-06-25 2006-02-20 Джинентех, Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО
JP4028237B2 (ja) 1999-10-29 2007-12-26 ジェネンテック・インコーポレーテッド 抗前立腺幹細胞抗原（ｐｓｃａ）抗体組成物及び使用方法
AU2001273432A1 (en) 2000-07-13 2002-01-30 Invitrogen Corporation Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20030170810A1 (en) 2001-09-18 2003-09-11 Masoud Vedadi Methods and apparatuses for purification
WO2003033656A2 (en) 2001-10-16 2003-04-24 Exelixis, Inc. MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE
WO2003033658A2 (en) 2001-10-17 2003-04-24 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
CN1206240C (zh) * 2003-04-07 2005-06-15 中国科学院生态环境研究中心 高效离子交换膜色谱纯化卵黄蛋白原技术
WO2005000901A2 (en) 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US20080274501A1 (en) * 2007-05-02 2008-11-06 Chenming Zhang Method of purifying acidic proteins expressed in plants
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
EP2226331A4 (en) 2007-10-26 2012-02-08 Asahi Kasei Chemicals Corp PROCESS FOR CLEANING PROTEINS
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
WO2009135656A1 (en) * 2008-05-06 2009-11-12 Lonza Biologics Plc. A method for the purification of antibodies using displacement chromatography
CN102149724B (zh) * 2008-08-14 2014-04-09 健泰科生物技术公司 使用原地蛋白质置换离子交换膜层析清除污染物的方法
GB0816242D0 (en) 2008-09-05 2008-10-15 Immunobiology Ltd Method of purifying protien complexes
SG178276A1 (en) 2009-08-06 2012-03-29 Genentech Inc Method to improve virus removal in protein purification
KR101764449B1 (ko) * 2009-09-01 2017-08-02 제넨테크, 인크. 변형된 단백질 ａ 용리를 통한 증진된 단백질 정제
US9637557B2 (en) * 2010-04-23 2017-05-02 Genentech, Inc. Production of heteromultimeric proteins
SG10201710439UA (en) * 2010-05-25 2018-01-30 Genentech Inc Methods of purifying polypeptides
CA2850765A1 (en) * 2011-10-03 2013-04-11 Sachem, Inc. Anionic displacer molecules for hydrophobic displacement chromatography
HRP20181846T1 (hr) * 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
JP7402011B2 (ja) 2023-12-20
MX2018013356A (es) 2020-09-14
US20200102346A1 (en) 2020-04-02
CN104125963A (zh) 2014-10-29
CA2859376A1 (en) 2013-06-27
MY172426A (en) 2019-11-25
HRP20181846T1 (hr) 2018-12-28
BR112014015101A2 (pt) 2017-06-13
ZA201404593B (en) 2022-12-21
RU2648999C2 (ru) 2018-03-29
MX360453B (es) 2018-11-01
JP2015503524A (ja) 2015-02-02
US20240247027A1 (en) 2024-07-25
MX2014007622A (es) 2014-09-22
NZ626949A (en) 2016-11-25
IL267585B (en) 2022-09-01
CN108892706A (zh) 2018-11-27
SI2794635T1 (sl) 2018-12-31
KR20210025692A (ko) 2021-03-09
KR102067075B1 (ko) 2020-01-17
JP2021169454A (ja) 2021-10-28
IL267585A (en) 2019-08-29
US20140348845A1 (en) 2014-11-27
AU2012355356A1 (en) 2014-07-10
EP3492486A1 (en) 2019-06-05
AR089362A1 (es) 2014-08-20
TR201815709T4 (tr) 2018-11-21
KR20200008022A (ko) 2020-01-22
JP2018109024A (ja) 2018-07-12
US11945837B2 (en) 2024-04-02
JP2022101557A (ja) 2022-07-06
WO2013096322A8 (en) 2014-02-27
RU2014130017A (ru) 2016-02-10
CN104125963B (zh) 2018-08-17
PL2794635T3 (pl) 2019-02-28
IL233158A0 (en) 2014-07-31
JP2020040952A (ja) 2020-03-19
SG11201403437TA (en) 2014-07-30
WO2013096322A1 (en) 2013-06-27
KR20140114834A (ko) 2014-09-29
JP7359807B2 (ja) 2023-10-11
AU2012355356B2 (en) 2017-10-12
EP2794635A1 (en) 2014-10-29
IL233158B (en) 2019-07-31
AU2018200194A1 (en) 2018-02-01
ZA201903994B (en) 2023-12-20
JP6605202B2 (ja) 2019-11-13
WO2013096322A9 (en) 2013-08-22
US10364268B2 (en) 2019-07-30
HK1203526A1 (en) 2015-10-30
EP2794635B1 (en) 2018-09-12
ES2697676T3 (es) 2019-01-25
AU2018200194B2 (en) 2019-11-14
CA2859376C (en) 2022-04-19
EP2794635B8 (en) 2018-11-14
AU2020201070A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
BR112014015101A8 (pt) métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
CY1122221T1 (el) Μεθοδοι αφαιρεσης ρυπου χρησιμοποιωντας ιοντοανταλλακτικη μεμβρανικη χρωματογραφια μετατοπισης γηγενων πρωτεϊνων
BR112012017124A2 (pt) método de modificação polipeptídica para purificação de multímeros polipeptídicos
RU2011137030A (ru) Способы очистки малых модулярных иммунофармацевтических белков
BR112015031196A2 (pt) “processo de purificação de anticorpo monoclonal”
BR112017018365A2 (pt) uso de lavagens alcalinas durante cromatografia para remoção de impurezas
ME02162B (me) Proces prečišćavanja proteina
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
BR112012009289B8 (pt) método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
BR112015014751A2 (pt) anticorpos anti-tau humanos
BR112018075516A2 (pt) purificação de anticorpos multiespecíficos
RU2014111820A (ru) Способы элиминации вируса
BR112013019508A2 (pt) purificação de insulina
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
MX2018000505A (es) Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos.
MA40510A (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
AR053632A1 (es) Metoddos para purificar anticuerpos anti a beta
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
BR112013030628A2 (pt) "métodos para produção de uma proteína purificada de interesse utilizando uma matriz de cromatografia de afinidade (ca), e de um anticorpo purificado, fragmento de anticorpo ou proteína de fusão de fc utilizando a coluna de proteína a".
BR112013000623A2 (pt) purificação de proteína.
BR112012014937A2 (pt) solução de lavagem e método para cromatografia de afinidade
PE20150720A1 (es) Purificacion de iduronato-2-sulfatasa
BR112012024956A2 (pt) processo para a purificação de uma proteína de fator de crescimento
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]